A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
Conditions
Ovary
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.
- Ages18 years and older
- GenderFemale only
- Trial withAravive, Inc.
- Start Date11/11/2021
- End Date07/24/2023
For more information about this study, contact:
Elizabeth Vitale
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated11/12/2021
- Study HIC#2000030390